Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
IndexS&P 500 P/E- EPS (ttm)-0.82 Insider Own0.80% Shs Outstand189.89M Perf Week6.87%
Market Cap10.99B Forward P/E- EPS next Y-1.57 Insider Trans-39.34% Shs Float170.27M Perf Month-32.56%
Income-128.60M PEG- EPS next Q5.22 Inst Own93.30% Short Float7.45% Perf Quarter-43.83%
Sales321.00M P/S34.23 EPS this Y43.60% Inst Trans2.01% Short Ratio2.97 Perf Half Y2.17%
Book/sh0.36 P/B160.72 EPS next Y-143.10% ROA-24.90% Target Price101.56 Perf Year219.85%
Cash/sh1.56 P/C37.03 EPS next 5Y-7.30% ROE-220.20% 52W Range17.51 - 111.36 Perf YTD-3.11%
Dividend- P/FCF- EPS past 5Y16.20% ROI-18.10% 52W High-48.35% Beta1.76
Dividend %- Quick Ratio4.00 Sales past 5Y30.50% Gross Margin90.30% 52W Low228.50% ATR6.11
Employees509 Current Ratio4.20 Sales Q/Q53.80% Oper. Margin-28.60% RSI (14)38.06 Volatility5.82% 8.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-43.30% Profit Margin-40.10% Rel Volume0.15 Prev Close57.86
ShortableYes LT Debt/Eq4.21 EarningsMay 10 AMC Payout- Avg Volume4.27M Price57.52
Recom1.80 SMA20-16.22% SMA50-27.95% SMA200-8.71% Volume32,204 Change-0.59%
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-30-16Resumed Brean Capital Buy
Jan-07-16Reiterated Piper Jaffray Overweight $16 → $20
Mar-18-15Reiterated ROTH Capital Buy $21 → $19
Mar-18-15Reiterated Brean Capital Buy $20 → $17
Sep-16-14Reiterated Brean Capital Buy $18 → $20
Jun-18-18 08:20AM  Today's Research Reports on Trending Tickers: Verastem and Nektar Therapeutics ACCESSWIRE
Jun-14-18 10:00AM  New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting PR Newswire +5.50%
Jun-11-18 02:58PM  Former Incyte CEO Buys Slumping Nektar Shares Barrons.com
11:14AM  Biotech, Nektar Therapeutics Can't Handle Mondays Barrons.com
Jun-10-18 05:29PM  The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs Benzinga
Jun-08-18 03:24AM  [$$] Are you following the wrong small-cap index? Financial Times
Jun-07-18 09:09PM  Why Nektar Therapeutics Stock Stumbled 11.8% Today Motley Fool -11.69%
06:34PM  After the Bell: 21 Out of 30 Dow Stocks Can't Be Wrong, Can They? Barrons.com
Jun-06-18 07:06PM  After the Bell: Dow Gains 346 Points and Didn't Need Tech to Do It Barrons.com +7.18%
04:32PM  Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today Motley Fool
04:15PM  Here's Why Nektar Therapeutics Jumped as Much as 17% Today Motley Fool
04:05PM  Nektar Attempts Recovery After Knocking $6 Billion Off Its Market Cap Investor's Business Daily
08:54AM  Nektar Therapeutics (NKTR) Jumps: Stock Rises 6.5% Zacks
08:29AM  ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks
Jun-05-18 06:50PM  Cramer's lightning round: 'I beg you' to hold the stock of Hasbro CNBC +6.45%
01:50PM  Kohl's, Freeport McMoRan, Twitter, Nektar Therapeutics & ... CNBC Videos
12:59PM  Nektar's Sole Skeptic Warns of Parallels to Biggest Biotech Flop Bloomberg
11:00AM  Nektar Therapeutics Stock Is a Buy After a Major Market Misread InvestorPlace
09:46AM  Company News For Jun 5, 2018 Zacks
08:42AM  Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study Zacks
08:30AM  Nektar to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York PR Newswire
08:20AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Align Technology ACCESSWIRE
08:13AM  Do Nektars disappointing clinical trial results invalidate $2 billion Bristol-Myers deal? MarketWatch
Jun-04-18 07:46PM  [$$] In Biotech, $6 Billion Can Vanish Quickly The Wall Street Journal -41.82%
05:14PM  Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug TheStreet.com
05:14PM  After the Bell: Dow Gains 178 Points as Risk Takes a Holiday Barrons.com
04:46PM  Merck and TJX climb; Nektar Therapeutics slumps Associated Press
04:40PM  Is Nektar Therapeutics Stock a Bargain Now? Motley Fool
04:31PM  Why Canadian Solar, Nektar Therapeutics, and Gulfport Energy Slumped Today Motley Fool
04:30PM  Nektars 42% Plunge Gives It a Record That No Company Wants Bloomberg
04:21PM  Here Are Winners And Losers From 2018's Biggest Cancer Drug Meeting Investor's Business Daily
04:01PM  Tech is the new capex, it's a cyclical play: Pro CNBC Videos
03:56PM  $15 billion biotech stock loses more than 40% of its value after skin cancer drug study falls short CNBC
02:30PM  Why Bristol-Myers Squibb Company Shares Are Down Today InvestorPlace
01:49PM  [$$] Nektar's 39% Drop: A New Record for a Volatile Stock Barrons.com
01:45PM  Why Nektar Therapeutics Shares Are Plunging Today InvestorPlace
01:18PM  5 Biotech Stocks Moving On ASCO Presentations Benzinga
11:53AM  Nektar's 40% Plunge Is Compounded By Risky Cancer-Drug Bet Bloomberg
11:43AM  [$$] In Biotech, $6 Billion Can Vanish Quickly The Wall Street Journal
11:37AM  Nektar Roiled by Cancer Data, Other Biotechs Gain Barrons.com
09:39AM  Nektar shares drop 35% on 'underwhelming' cancer trial data MarketWatch
09:22AM  Morning Movers: Nektar Tumbles 28%, Facebook Falls, Whirlpool Rallies Barrons.com
09:14AM  Winners And Losers From Cancer Research's Biggest Event Forbes
08:35AM  Is the Options Market Predicting a Spike in Nektar (NKTR) Stock? Zacks
05:00AM  Nektar Plummets on Concerns Over Cancer-Drug Trial Results Bloomberg
Jun-03-18 09:49PM  Mixed results for Bristol/Nektar combination in cancer trial Reuters
02:10PM  #ASCO18: A Weekend of Surprises Motley Fool
Jun-02-18 06:10PM  Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018 PR Newswire
Jun-01-18 07:59PM  After the Bell: Dow's Payroll Rally Not Enough to Erase Wild Week's Losses Barrons.com +12.56%
04:32PM  Why Nektar Therapeutics, Ambac Financial Group, and Zuora Jumped Today Motley Fool
10:24AM  Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate Zacks
May-31-18 10:00PM  Can Nektar Therapeutics Disrupt This $20 Billion Market? Motley Fool
08:15AM  Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy PR Newswire
May-30-18 04:05PM  Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration PR Newswire
May-29-18 07:20AM  Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desks Radar ACCESSWIRE
May-21-18 08:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Corcept Therapeutics ACCESSWIRE
May-18-18 05:03PM  After the Bell: Dow Ends Week Slightly in the Red Because Only Small Caps Rise in This Market Barrons.com +7.66%
04:51PM  Winners and Losers From the Biggest Cancer Meeting of the Year (So Far) Motley Fool
04:32PM  Why Dell Technologies, Nektar Therapeutics, and Westport Fuel Systems Jumped Today Motley Fool
08:10AM  Todays Research Reports on Stocks to Watch: Eiger BioPharmaceuticals and Nektar Therapeutics ACCESSWIRE
May-17-18 05:34PM  After the Bell: Dow Drops 55 Points, Small-Caps Soar to a New High Barrons.com -7.66%
01:38PM  Here's Why Nektar Therapeutics Fell as Much as 11.1% Today Motley Fool
May-16-18 07:45PM  Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
May-15-18 02:28PM  Nektar Therapeutics Stock Is Risky But Offers Big Reward InvestorPlace
06:33AM  These 3 Stocks Have Doubled Investors' Money Motley Fool
May-14-18 09:44AM  Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y Zacks
May-11-18 09:56PM  Edited Transcript of NKTR earnings conference call or presentation 10-May-18 9:00pm GMT Thomson Reuters StreetEvents
07:21AM  3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies Inc (SEDG) InvestorPlace
May-10-18 04:24PM  Nektar: 1Q Earnings Snapshot Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 PR Newswire
08:16AM  [$$] 100 Days of Volatility: Yes, It's Been That Wild Barrons.com
May-08-18 08:30AM  Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus PR Newswire
07:32AM  Jim Cramer Advises His Viewers On Prestige Brands, CVS Health And More Benzinga
May-07-18 08:20AM  Today's Research Reports on Trending Tickers: Geron Corporation and Nektar Therapeutics ACCESSWIRE
May-03-18 01:52PM  Biotech: Nektar's Stock May Fall 15% Further Investopedia
08:45AM  Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets PR Newswire
Apr-30-18 04:47PM  Can These Top-Performing Biotech Stocks Keep Climbing? Motley Fool
08:36AM  Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting PR Newswire
Apr-24-18 09:48AM  Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar? Zacks
08:30AM  New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors PR Newswire
Apr-17-18 08:20AM  Todays Research Reports on Stocks to Watch: Nektar Therapeutics and Merck & Co. ACCESSWIRE
Apr-16-18 08:30AM  Todays Research Reports on Trending Tickers: Valeant Pharmaceuticals and Nektar Therapeutics ACCESSWIRE -7.00%
Apr-15-18 06:00PM  Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018 PR Newswire
Apr-13-18 08:18AM  These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years Motley Fool
Apr-12-18 10:37AM  Nektar Starts Phase I/II Combo for Advanced Solid Tumors Zacks
Apr-11-18 11:10AM  Stocks Selling Off Harder But These Small Caps Are Worth A Look Investor's Business Daily
08:00AM  Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors PR Newswire
Apr-10-18 08:30AM  Todays Research Reports on Trending Tickers: Clovis Oncology and Nektar Therapeutics ACCESSWIRE
Apr-08-18 11:50AM  Here's Why Nektar Therapeutics Jumped 23% Higher in March Motley Fool
Apr-07-18 11:48AM  These S&P Stocks Jumped 50% in the 1st Quarter Motley Fool
Apr-06-18 03:59PM  How a Biotech Bummer Sent Nektar Therapeutics Stock South Today Motley Fool -7.46%
02:39PM  Benzinga's Top Analyst Calls From April 6, 2018 Benzinga
01:16PM  Biotech Investors Should Consider The Four Horsemen Forbes
Apr-03-18 05:30PM  Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb PR Newswire
Apr-02-18 04:48PM  The Biggest Movers: Humana Jumps, Nektar Tumbles Barrons.com -7.05%
09:22AM  3 Biotech Stocks Hitting New Highs Investopedia
Mar-30-18 10:19AM  The S&P 500s 10 Biggest Winners of the Quarter: Nektar Soars Barrons.com
Mar-21-18 03:43PM  Why It's So Dang Hard to Value Biotech Deals Motley Fool
11:59AM  Harry Boxers four stock charts to watch, including Squares MarketWatch
Mar-19-18 09:02PM  These Stocks Have Quadrupled Since Mid-2017 Motley Fool
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GREER R SCOTTDirectorJun 06Option Exercise5.148,60044,204138,933Jun 06 07:42 PM
WHITFIELD ROY ADirectorJun 06Buy59.373,400201,860177,000Jun 07 07:40 PM
GREER R SCOTTDirectorJun 06Sale60.008,600516,000130,333Jun 06 07:42 PM
CHESS ROBERTDirectorJun 05Option Exercise14.2610,000142,600284,223Jun 07 07:39 PM
WHITFIELD ROY ADirectorJun 05Buy55.221,60088,352173,600Jun 07 07:40 PM
CHESS ROBERTDirectorJun 05Sale55.1610,000551,600274,223Jun 07 07:39 PM
GREER R SCOTTDirectorJun 04Option Exercise5.141,4007,196131,733Jun 06 07:42 PM
GREER R SCOTTDirectorJun 04Sale61.991,40086,786130,333Jun 06 07:42 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale83.393,435286,44563,959May 18 07:01 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale83.394,060338,56376,201May 18 07:02 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale83.394,941412,03094,798May 18 07:03 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale83.394,917410,029162,596May 18 07:05 PM
ROBIN HOWARD WPresident & CEOMay 16Sale83.3912,7911,066,641224,356May 18 07:06 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale83.393,576298,20365,281May 18 07:07 PM
CHESS ROBERTDirectorMay 03Option Exercise8.7925,000219,700289,223May 04 06:55 PM
ROBIN HOWARD WPresident & CEOMay 03Option Exercise10.6943,333463,230280,480May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Sale82.8630,0002,485,80099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 03Sale82.8643,3333,590,572237,147May 03 08:42 PM
CHESS ROBERTDirectorMay 03Sale82.8025,0002,070,050274,223May 04 06:55 PM
ROBIN HOWARD WPresident & CEOMay 02Option Exercise10.6943,333463,230280,480May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Sale85.6330,0002,568,90099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 02Sale85.6343,3333,710,605237,147May 03 08:42 PM
ROBIN HOWARD WPresident & CEOMay 01Option Exercise10.6943,334463,240280,481May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Sale83.6530,0002,509,50099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 01Sale83.6543,3343,624,889237,147May 03 08:42 PM
WHITFIELD ROY ADirectorApr 17Option Exercise14.2630,000427,800172,000Apr 18 06:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Option Exercise10.6913,881148,38882,738Apr 18 06:03 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Sale101.4613,8811,408,36668,857Apr 18 06:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Option Exercise7.215023,61980,763Apr 12 06:05 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Sale105.6750253,04680,261Apr 12 06:05 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Option Exercise7.2149,500356,895116,894Apr 09 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Option Exercise7.219,49868,48189,759Apr 09 08:22 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Sale105.059,498997,76580,261Apr 09 08:22 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Sale96.1349,5004,758,43567,394Apr 09 08:21 PM
CHESS ROBERTDirectorApr 06Option Exercise8.7925,000219,700289,223Apr 09 08:20 PM
GREER R SCOTTDirectorApr 06Option Exercise14.2630,000427,800160,333Apr 09 08:22 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Option Exercise9.10110,5001,005,505177,894Apr 09 08:21 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Sale91.69110,50010,131,74567,394Apr 09 08:21 PM
GREER R SCOTTDirectorApr 06Sale92.2230,0002,766,600130,333Apr 09 08:22 PM
CHESS ROBERTDirectorApr 06Sale92.1425,0002,303,600274,223Apr 09 08:20 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Option Exercise7.2120,000144,200100,261Apr 09 08:22 PM
Lingnau LutzDirectorApr 05Option Exercise9.2430,000277,20057,450Apr 09 08:23 PM
Lingnau LutzDirectorApr 05Sale101.7430,0003,052,20027,450Apr 09 08:23 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Sale101.7520,0002,035,00080,261Apr 09 08:22 PM
KUEBLER CHRISTOPHER ADirectorMar 07Option Exercise6.2437,400233,23677,900Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 07Sale97.4137,4003,643,13440,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 07Sale100.45100,14410,059,465167,513Mar 08 06:09 PM
KUEBLER CHRISTOPHER ADirectorMar 06Option Exercise5.142,60013,36443,100Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 06Sale100.302,600260,78040,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 06Sale98.29120,00011,794,800267,657Mar 08 06:09 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale82.942,545211,08268,857Feb 20 07:10 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 16Sale82.944,879404,664387,657Feb 20 07:09 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale82.9412,7881,060,637237,147Feb 20 07:10 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 16Sale82.942,875238,45380,261Feb 20 07:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 16Sale82.943,477288,38299,739Feb 20 07:08 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 16Sale82.942,426201,21267,394Feb 20 07:07 PM
Nicholson JohnSVP & Chief Operating OfficerJan 31Option Exercise11.34120,0001,360,800392,536Feb 02 06:03 PM
ROBIN HOWARD WPresident & CEOJan 22Option Exercise11.3483,333944,996333,268Jan 24 06:01 PM
ROBIN HOWARD WPresident & CEOJan 22Sale75.8283,3336,318,308249,935Jan 24 06:01 PM
WINGER DENNIS LDirectorJan 04Option Exercise11.9733,750403,98877,000Jan 08 06:07 PM
KUEBLER CHRISTOPHER ADirectorJan 02Option Exercise14.2630,000427,80070,500Jan 04 06:01 PM
KUEBLER CHRISTOPHER ADirectorJan 02Sale58.6630,0001,759,80040,500Jan 04 06:01 PM
ROBIN HOWARD WPresident & CEODec 13Option Exercise11.3483,333944,996272,768Dec 15 06:00 PM
ROBIN HOWARD WPresident & CEODec 13Sale55.6983,3334,640,815189,435Dec 15 06:00 PM
Nicholson JohnSVP & Chief Operating OfficerNov 13Option Exercise9.2425,000231,000249,066Nov 15 06:02 PM
Nicholson JohnSVP & Chief Operating OfficerNov 13Sale37.7815,910601,080233,156Nov 15 06:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 08Option Exercise9.53300,0002,859,000331,102Nov 08 06:01 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 08Sale30.09300,0009,027,00031,102Nov 08 06:01 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 07Option Exercise9.5375,409718,648106,511Nov 08 06:01 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 07Option Exercise10.6917,300184,93775,533Nov 08 06:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 07Sale25.7875,4091,944,04431,102Nov 08 06:01 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 06Option Exercise9.5320,914199,31052,016Nov 08 06:01 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 06Option Exercise10.695,11754,70163,350Nov 08 06:02 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 06Sale25.075,117128,28358,233Nov 08 06:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 06Sale24.9820,914522,43231,102Nov 08 06:01 PM
ROBIN HOWARD WPresident & CEONov 01Option Exercise11.3483,334945,008235,838Nov 03 06:07 PM
ROBIN HOWARD WPresident & CEONov 01Sale23.5783,3341,964,182152,504Nov 03 06:07 PM
ROBIN HOWARD WPresident & CEOOct 09Option Exercise11.3483,333944,996235,837Oct 10 06:08 PM
ROBIN HOWARD WPresident & CEOOct 09Sale24.2083,3332,016,659152,504Oct 10 06:08 PM
Doberstein Stephen KSVP & Chief Scientific OfficerOct 05Option Exercise9.5343,677416,24274,779Oct 10 06:06 PM
Hora ManinderSVP Pharma Dev & Mfg OpsOct 05Option Exercise10.697,58381,06265,816Oct 10 06:07 PM
Hora ManinderSVP Pharma Dev & Mfg OpsOct 05Sale25.007,583189,57558,233Oct 10 06:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerOct 05Sale24.9743,6771,090,61531,102Oct 10 06:06 PM
Gergel Ivan P.SVP & Chief Medical OfficerOct 02Option Exercise11.0456,704626,01298,279Oct 03 06:02 PM
Labrucherie Gil MSVP & Chief Financial OfficerOct 02Option Exercise11.34120,0001,360,800183,414Oct 03 06:06 PM
Labrucherie Gil MSVP & Chief Financial OfficerOct 02Sale24.45120,0002,934,00063,414Oct 03 06:06 PM
Gergel Ivan P.SVP & Chief Medical OfficerOct 02Sale24.2156,7041,372,80441,575Oct 03 06:02 PM
Gergel Ivan P.SVP & Chief Medical OfficerSep 29Option Exercise11.0443,296477,98884,871Oct 03 06:02 PM
Gergel Ivan P.SVP & Chief Medical OfficerSep 29Sale24.0443,2961,040,83641,575Oct 03 06:02 PM
Lingnau LutzDirectorSep 22Sale21.975,000109,85027,450Sep 25 06:04 PM
KUEBLER CHRISTOPHER ADirectorSep 22Sale21.864,00087,44040,500Sep 25 06:03 PM
CHESS ROBERTDirectorSep 21Sale21.726,400139,008274,223Sep 25 06:02 PM
ROBIN HOWARD WPresident & CEOSep 06Option Exercise11.3483,333944,996235,837Sep 08 06:08 PM
ROBIN HOWARD WPresident & CEOSep 06Sale21.5483,3331,794,993152,504Sep 08 06:08 PM
ROBIN HOWARD WPresident & CEOAug 16Option Exercise11.3483,334945,008235,838Aug 18 07:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale19.322,64851,15950,838Aug 18 07:05 PM
Nicholson JohnSVP & Chief Operating OfficerAug 16Sale19.323,17761,380224,066Aug 18 07:04 PM